Paid Clinical Trials in Tennessee

Tennessee has 2,062 paid clinical trials enrolling now across cities including Nashville, Memphis and Knoxville. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Research sites in Tennessee include Vanderbilt University Medical Center and St. Jude Children's Research Hospital, running studies across oncology, cardiology, neurology, and more. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 14, 2026.

Filter results

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,839 clinical trials

Get a weekly email when new trials open in Nashville, TN.

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

Sites in Nashville +3 more locations

Sponsor: AbbVie

Sex: All·Age: 6 Months - 17

Code: NCT07306832·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

for Locally Advanced or Metastatic Malignant Solid Tumors

Sites in Nashville +3 more locations

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07287995·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

for Lymphoma Diffuse Large B-cell

Sites in Nashville +4 more locations

Sponsor: AvenCell Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07284433·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform

for High-risk Cardiac Patients

1 location in Nashville

Sponsor: Idoven 1903 S.L.

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07333547·Recruiting·Listed Jan 2026

Apply to this trial

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

for Advanced HR+/HER2- Breast Cancer

Drug: GVV858

Sites in Nashville +2 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07288359·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

for Renal Cell Carcinoma

Sites in Knoxville +9 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07227402·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of BI 3810944 in Patients With Advanced Cancer

for Solid Tumours

Sites in Nashville +3 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07224425·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

for Atopic Keratoconjunctivitis

Sites in Memphis +7 more locations

Sponsor: Dompé Farmaceutici S.p.A

Sex: All·Age: 18 - 65

Code: NCT07395232·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.

for Ankle Arthrodesis or Arthroplasty

Sites in Chattanooga +6 more locations

Sponsor: Kuros Biosurgery AG

Sex: All·Age: 18 - 75

Code: NCT07225751·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

for Advanced Solid Tumor

Sites in Nashville +3 more locations

Sponsor: Ipsen

Sex: All·Age: 18+

Code: NCT07213830·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

for Prader-Willi Syndrome

1 location in Nashville

Sponsor: ConSynance Therapeutics

Sex: All·Age: 13 - 50

Code: NCT07348601·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

for Solid Tumors

Sites in Nashville +7 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07195916·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

Drug: Nucresiran

Sites in Nashville +9 more locations

Sponsor: Alnylam Pharmaceuticals

Sex: All·Age: 18 - 85

Code: NCT07223203·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

for Advanced Stage Solid Tumors

Sites in Nashville +3 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07107230·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

for Renal Cell Carcinoma

Drug: BMS-986506

Sites in Nashville +4 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07195682·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for Breast Neoplasms

Sites in Nashville +7 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06797635·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

for Cancer

Sites in Nashville +6 more locations

Sponsor: Angiex, Inc.

Sex: All·Age: 18+

Code: NCT06440005·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

for Lymphoma

Sites in Nashville +7 more locations

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07082803·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

Study in Advanced Solid Tumor Patients

for Advanced Solid Tumor

Sites in Nashville +4 more locations

Sponsor: Callio Therapeutics

Sex: All·Age: 18+

Code: NCT07300943·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

TLN-372 in Advanced KRAS Mutant Solid Tumors

for KRAS Mutant Solid Tumors

Sites in Nashville +5 more locations

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07204340·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

for Non-Small Cell Lung Cancer

Sites in Nashville +8 more locations

Sponsor: Pierre Fabre Medicament

Sex: All·Age: 18+

Code: NCT06043817·Phase 1, Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

A Study of CTD402 in T-ALL/LBL Patients

for Acute Lymphocytic Leukemia Refractory

Sites in Nashville +6 more locations

Sponsor: Imviva Bio

Sex: All·Age: 1+

Code: NCT07070219·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for Advanced Solid Tumors

Sites in Nashville +8 more locations

Sponsor: Accent Therapeutics

Sex: All·Age: 18+

Code: NCT06799065·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

for Esophageal Squamous Cell Carcinoma

Sites in Nashville, Memphis +11 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06644781·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Hepatocellular Carcinoma

Drug: Bevacizumab

Sites in Nashville +6 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06427941·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

for Short Bowel Syndrome

Sites in Nashville +4 more locations

Sponsor: Zealand Pharma

Sex: All·Age: 18 - 90

Code: NCT07197944·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

for Breast Cancer

Sites in Nashville +2 more locations

Sponsor: MBQ Pharma

Sex: All·Age: 21+

Code: NCT06075810·Phase 1·Recruiting·Listed Oct 2023

Apply to this trial

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

for Advanced HR+/HER2- Breast Cancer

Sites in Nashville +7 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06726148·Phase 1, Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

for Breast Cancer

Sites in Germantown +3 more locations

Sponsor: Hoffmann-La Roche

Sex: Female·Age: 18+

Code: NCT07054190·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

for Osteogenesis Imperfecta (OI)

Sites in Nashville +8 more locations

Sponsor: Angitia Incorporated Limited

Sex: All·Age: 18 - 75

Code: NCT07062588·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

for Colorectal Cancer

Sites in Nashville +12 more locations

Sponsor: Criterium, Inc.

Sex: All·Age: 18+

Code: NCT06992258·Phase 2·Recruiting·Listed May 2025

Apply to this trial

SMP-3124LP in Adults With Advanced Solid Tumors

for Solid Tumor

Sites in Nashville +9 more locations

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT06526819·Phase 1, Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

for Castration-Resistant Prostatic Cancer

Sites in Germantown +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06863272·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for Small Cell Lung Cancer

Drug: Gocatamig

Sites in Nashville +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06780137·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

for Hemophilia B

Sites in Memphis +4 more locations

Sponsor: CSL Behring

Sex: Male·Age: 138 Months - 206 Months

Code: NCT07080905·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

for Solid Tumors

Sites in Nashville +2 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06644755·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

for Solid Tumor, Adult

Sites in Nashville +1 more location

Sponsor: Rise Therapeutics LLC

Sex: All·Age: 18 - 80

Code: NCT06398418·Phase 1·Recruiting·Listed May 2024

Apply to this trial

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

for Advanced Solid Tumor

Sites in Nashville +4 more locations

Sponsor: Ipsen

Sex: All·Age: 18+

Code: NCT06833008·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

for Non-small Cell Lung Cancer (NSCLC)

Sites in Nashville +1 more location

Sponsor: Pierre Fabre Medicament

Sex: All·Age: 18+

Code: NCT06567015·Phase 1, Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Sites in Nashville +7 more locations

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07140900·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial